Fred Callori - 16 May 2022 Form 4 Insider Report for Landos Biopharma, Inc.

Role
Director
Signature
/s/ Eric W. Blanchard, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
16 May 2022
Net transactions value
$0
Form type
4
Filing time
18 May 2022, 16:30:00 UTC
Previous filing
31 Aug 2021
Next filing
09 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LABP Stock Option (right to buy) Award $0 +18,000 $0.000000 18,000 16 May 2022 Common Stock 18,000 $0.6434 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/12th of the shares subject to this option will vest and become exercisable in equal monthly installments commencing May 19, 2022, subject to the Reporting Person providing continuous service to the Issuer.